热景生物(688068.SH)子公司SGC001创新药Ⅱ期临床研究完成首例受试者入组给药

智通财经03-10

智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司控股子公司北京舜景生物医药技术有限公司(简称“舜景医药”)自主研发的创新药SGC001注射液Ⅱ期临床研究完成首例受试者入组给药。由舜景医药开展的“一项评估SGC001注射液在中国急性前壁ST段抬高型心肌梗死且计划接受直接经皮冠状动脉介入(pPCI)治疗的患者中的有效性、安全性、药代动力学特征的随机、双盲、安慰剂对照的II期临床研究...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618933945?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-10 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618933945","market":"hk","top_or_hot":-1,"title":"热景生物(688068.SH)子公司SGC001创新药Ⅱ期临床研究完成首例受试者入组给药","media":"智通财经","content":"<div>\n<p>智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司控股子公司北京舜景生物医药技术有限公司(简称“舜景医药”)自主研发的创新药SGC001注射液Ⅱ期临床研究完成首例受试者入组给药。由舜景医药开展的“一项评估SGC001注射液在中国急性前壁ST段抬高型心肌梗死且计划接受直接经皮冠状动脉介入(pPCI)治疗的患者中的有效性、安全性、药代动力学特征的随机、双盲、安慰剂对照的II期临床研究...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1412155.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>热景生物(688068.SH)子公司SGC001创新药Ⅱ期临床研究完成首例受试者入组给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n热景生物(688068.SH)子公司SGC001创新药Ⅱ期临床研究完成首例受试者入组给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 17:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1412155.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司控股子公司北京舜景生物医药技术有限公司(简称“舜景医药”)自主研发的创新药SGC001注射液Ⅱ期临床研究完成首例受试者入组给药。由舜景医药开展的“一项评估SGC001注射液在中国急性前壁ST段抬高型心肌梗死且计划接受直接经皮冠状动脉介入(pPCI)治疗的患者中的有效性、安全性、药代动力学特征的随机、双盲、安慰剂对照的II期临床研究...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1412155.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688068","symbol_name":"热景生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1412155.html","article_id":"2618933945","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618933945","pubTimestamp":1773133636,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，热景生物 发布公告，近日，公司控股子公司北京舜景生物医药技术有限公司自主研发的创新药SGC001注射液Ⅱ期临床研究完成首例受试者入组给药。研究于2026年初率先在上海市东方医院启动，并于2026年3月9日在山西省临汾市中心医院范甲卯教授带领下完成首例受试者入组及给药。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","688068":"热景生物","BK0239":"医药制造","BK1161":"生物科技","BK1574":"生物医药B类股","06978":"永泰生物-B"},"translate_title":"The Phase II clinical study of SGC001 innovative drug, a subsidiary of Rejing Biotech (688068.SH), completed the enrollment of the first subject","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"688068":1.5,"06978":1.5},"content_text":"智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司控股子公司北京舜景生物医药技术有限公司(简称“舜景医药”)自主研发的创新药SGC001注射液Ⅱ期临床研究完成首例受试者入组给药。由舜景医药开展的“一项评估SGC001注射液在中国急性前壁ST段抬高型心肌梗死且计划接受直接经皮冠状动脉介入(pPCI)治疗的患者中的有效性、安全性、药代动力学特征的随机、双盲、安慰剂对照的II期临床研究”，由北京大学第一医院霍勇教授和上海市东方医院何奔教授牵头，全国超过20家医院参加。研究于2026年初率先在上海市东方医院启动，并于2026年3月9日在山西省临汾市中心医院范甲卯教授带领下完成首例受试者入组及给药。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618933945","isCrawlerRequest":true}